vaccin
human
pathogen
fungi
rather
neglect
medic
need
year
ago
gain
step
public
health
prioriti
scale
awar
rise
medic
threat
repres
opportunist
fungal
infect
among
health
careassoci
infect
advanc
knowledg
fungal
pathogen
immun
respons
extraordinari
progress
biotechnolog
gener
enthusiasm
critic
new
tool
activ
passiv
antifung
vaccin
discoveri
antibodi
play
critic
role
protect
fungal
infect
greatli
contribut
advanc
field
recognit
almost
use
vaccin
viral
bacteri
pathogen
owe
protect
efficaci
neutral
opson
otherwis
effect
antibodi
overal
hope
year
ago
chanc
gener
approv
regulatori
author
one
antifung
vaccin
activ
passiv
use
human
next
year
particular
possibl
protect
multipl
opportunist
mycos
immunodepress
subject
singl
welldefin
glucanconjug
vaccin
elicit
directli
antifung
antibodi
may
import
step
achiev
public
health
goal
vaccin
repres
use
immunolog
applic
human
health
medic
tool
use
prophylact
allow
diseas
elimin
even
erad
caus
agent
happen
smallpox
hope
close
occur
poliomyel
diseas
elimin
variou
reason
bound
habitat
infect
organ
natur
histori
infect
imposs
unlik
yet
avail
protect
vaccin
effect
vaccin
procedur
result
effect
control
diseas
wit
diseas
hepat
b
measl
pertussi
cite
reach
goal
term
public
health
rank
diseas
erad
elimin
control
avail
safe
efficaci
vaccin
obvious
essenti
howev
critic
factor
also
definit
medic
need
given
vaccin
term
costbenefit
prospect
advantag
relat
exist
prevent
therapeut
measur
correct
identif
target
popul
vaccin
capabl
public
health
system
implement
effect
vaccin
polici
must
also
care
consid
includ
among
other
capac
persuad
healthi
subject
parent
guardian
case
pediatr
vaccin
person
societ
advantag
vaccin
weight
minim
though
actual
risk
advers
event
futur
benefit
avoid
diseas
transmiss
neighbour
final
utmost
import
also
establish
whether
diseas
could
contrast
prevent
vaccin
also
use
therapeut
vaccin
ie
vaccin
formul
could
use
ill
subject
excit
attract
approach
deserv
particular
attent
field
fungal
diseas
howev
therapeut
vaccin
success
use
fight
infect
far
provid
element
balanc
decis
undertak
vaccin
manufactur
establish
vaccin
prioriti
becom
particularli
cogent
case
diseas
either
true
incid
impact
public
health
unknown
identif
target
popul
problemat
fungal
diseas
human
exactli
case
point
besid
sever
geographicallylimit
rel
lowincid
deepseat
infect
instanc
coccidiomycosi
blastomycosi
incid
worldwid
infect
aspergillosi
cryptococcosi
candidiasi
last
case
possibl
except
vagin
candidiasi
typic
occur
immunocompromis
host
clinic
set
rais
remark
obstacl
rational
immunoprevent
even
therapeut
vaccin
mostli
due
difficulti
achiev
effici
longlast
immun
respons
identifi
could
realli
benefit
vaccin
establish
exactli
vaccin
thu
nt
make
surpris
fungal
vaccin
unfairli
place
rather
remot
room
public
health
build
wit
practic
absenc
inform
antifung
vaccin
one
renown
famou
textbook
vaccin
plotkin
orenstein
special
editori
overview
line
descript
even
jordan
report
detail
state
art
document
annual
releas
nation
health
institut
said
sever
reason
evid
gather
last
year
command
scale
fungal
vaccin
human
rather
high
posit
prioriti
scale
strong
advocaci
recent
call
arm
immun
system
launch
steven
claim
vaccin
aspergillosi
fungal
diseas
nobodi
serious
think
vaccin
year
ago
well
upsurg
public
field
candida
vaccin
see
mochon
cutler
intent
first
discuss
evid
command
second
illustr
recent
advanc
field
fungal
vaccin
make
rather
optimist
achiev
least
coupl
effect
vaccin
next
year
final
focu
novelti
conceptu
advanc
come
area
fungal
vaccin
could
applic
vaccin
human
pathogen
repres
killertoxin
mimick
idiotyp
vaccin
conjug
vaccin
convers
attempt
made
cover
previous
publish
find
area
detail
mani
differ
vaccin
candid
adjuv
propos
variou
fungal
diseas
given
nonetheless
relev
inform
propos
vaccin
antigen
respect
refer
princip
agent
fungal
infect
human
given
tabl
tabl
offer
indic
promis
vaccin
candid
candida
rapidli
grow
field
number
antigen
also
discoveri
protect
antibodi
mechan
protect
mochon
cutler
moreov
mention
made
throughout
recent
propos
protect
fungal
antigen
activ
may
account
propos
immunolog
protect
final
veterinari
vaccin
dermatophyt
dealt
wish
go
detail
aspect
advis
read
number
excel
review
expert
opinion
publish
leader
area
quot
deep
deep
et
al
casadeval
et
al
cox
mage
feldmess
first
reason
support
need
gener
fungal
vaccin
overal
preval
incid
fungal
infect
markedli
increas
worldwid
special
concern
opportunist
agent
infect
restrict
two
frequent
among
latter
aspergillu
candida
spp
reason
estim
suggest
least
hospit
infect
caus
two
fungi
specif
attribut
mortal
case
itali
estim
incid
nosocomi
infect
vari
new
case
per
year
mean
minimum
subject
year
die
invas
fungal
infect
figur
much
larger
actual
death
rate
aid
countri
urciuoli
et
al
figur
rather
similar
industri
countri
organ
transplant
invas
surgeri
plethora
medic
condit
predispos
fungal
infect
similar
recent
survey
australian
investig
report
extra
case
aspergillosi
candidiasi
per
year
occur
hospit
patient
countri
slavin
et
al
particular
risk
subject
bone
marrow
transplant
subject
mortal
associ
aspergillosi
may
reach
figur
high
greater
sheppard
edward
recent
report
institut
medicin
us
emphas
nosocomi
infect
big
concernin
associ
thousand
death
year
lead
much
longer
hospit
stay
cours
tremend
cost
increas
ie
billion
dollar
addit
hospit
cost
year
aspergillosi
steven
report
nearli
death
occur
us
associ
hospit
day
million
usd
cost
estim
candida
incid
mostli
deriv
diseas
easili
diagnos
bloodstream
mucos
infect
particularli
candid
vagin
overal
fungu
becom
fourth
common
agent
bloodstream
infect
care
monitor
surveil
program
close
rate
respect
agent
bloodstream
infect
rise
incid
nonalbican
speci
intrins
refractori
one
antifung
sim
et
al
fungal
agent
also
becom
common
urinari
isol
although
case
etiolog
role
much
less
clear
side
mucos
infect
candida
long
known
common
immunocomprom
subject
also
appar
normal
one
specif
case
vagin
thrush
recurr
chronic
form
affect
substanti
percentag
women
suffer
initi
acut
attack
diseas
fidel
sobel
infect
may
irrevers
affect
qualiti
life
sinc
requir
chronic
hardli
compliabl
antimycot
treatment
enhanc
risk
acquir
antibiot
resist
focu
common
agent
opportunist
fungal
infect
worldwid
consid
disregard
agent
system
fungal
infect
endem
one
part
differ
contin
exampl
blastomycosi
coccidioidomycosi
paracoccidioidomycosi
interest
develop
vaccin
remain
quit
high
particularli
vaccin
coccidioid
speci
despit
geograph
limit
limit
number
subject
get
sick
follow
infect
soil
spore
question
one
side
imperfect
knowledg
whether
incid
rise
declin
side
difficulti
establish
treatment
capabl
elimin
focu
dormant
cell
potenti
constitut
lifelong
reactiv
threat
contrast
bacteri
infect
effect
diagnos
despit
strong
concern
spread
antibiot
resist
may
still
larg
cure
antibiot
fungal
infect
enjoy
rel
effect
treatment
remark
diagnost
difficulti
drug
use
combat
infect
also
endow
rather
seriou
sideeffect
reason
histor
pauciti
efficaci
antifung
treatment
basic
resid
difficulti
find
suitabl
target
select
drug
toxic
microrgan
eukaryot
host
coupl
delay
pharmaceut
industri
invest
drug
limit
market
compar
bacteri
viral
infect
gap
partial
fill
last
ten
year
particularli
novel
class
echinocandin
inhibit
glucan
synthesi
polak
also
becom
appar
antifung
drug
resist
sporad
episod
phenomenon
suspect
year
ago
may
rise
parallel
widespread
use
new
drug
sanglard
whole
scenario
want
either
avail
one
drug
instanc
activ
endem
mycos
exist
multipl
potenti
treatment
inevit
associ
antibiot
resist
instanc
chronic
mucos
candidiasi
mention
opportunist
invas
infect
fungi
also
suffer
remark
diagnost
difficulti
instanc
invas
candidiasi
diagnos
antemortem
less
patient
diagnost
insuffici
make
therapeut
treatment
antifung
delay
often
inappropri
truli
constitut
sound
rational
develop
immunolog
prevent
therapeut
approach
endem
fungal
infect
occur
otherwis
healthi
subject
either
therapeut
option
limit
trend
toward
antifung
drug
resist
emerg
possibl
associ
difficulti
prompt
specif
sensit
diagnosi
question
vaccin
target
simpli
answer
potenti
popul
group
defin
geograph
area
given
characterist
genet
occup
place
risk
diseas
relat
cost
nonspecif
intervent
cox
mage
may
also
appli
subject
risk
develop
fungal
infect
predispos
underli
condit
diabet
invas
surgeri
local
factor
system
immunedepress
extent
make
vaccin
unlik
rais
correct
protect
immun
respons
costbenefit
ratio
paramount
import
accur
inform
preval
diseas
factor
unfortun
case
unknown
much
complex
identif
target
popul
subject
deep
immunodepress
either
natur
immun
instanc
neutropen
subject
undergo
condit
chemotherapi
bone
marrow
transplant
adapt
immun
primari
acquir
cell
defici
aid
clearli
subject
unlik
respond
protect
vaccin
owe
partial
total
lack
immunecompet
rather
may
suffer
aggrav
immunolog
disord
follow
immunostimul
vaccin
antigen
adjuv
crucial
question
definit
risk
criteria
associ
likelihood
becom
ill
identifi
exactli
popul
higher
risk
could
justifi
cost
possibl
sideeffect
vaccin
becom
immunosuppress
discuss
activ
area
sever
indic
rather
high
number
subject
risk
could
inde
benefit
advanc
activ
immun
candida
aspergillu
may
also
includ
instanc
patient
candid
transplant
affect
tumour
therapi
predispos
fungal
infect
steven
sheppard
et
al
moreov
opportunist
agent
diseas
lowpenetr
virul
trait
immun
respons
contribut
control
usual
redund
imping
natur
adapt
immun
thu
vaccin
simpli
potenti
residu
set
immun
may
nonetheless
benefici
particular
case
point
observ
cell
activ
replac
induct
protect
histoplasmosi
model
cell
defici
mous
well
report
direct
anticandid
anticryptococc
activ
cytotox
cell
deep
levitz
et
al
clearli
issu
knowledg
type
immun
respons
help
host
rid
transmiss
agent
control
commens
fungu
probabl
critic
aspect
definit
prioriti
antifung
vaccin
aim
combat
opportunist
fungal
infect
consider
debat
whether
cellmedi
antibodi
respons
protect
arm
antifung
immun
put
term
fals
question
sinc
doubt
induct
fine
regul
cmi
particularli
thelper
type
respons
core
factor
antifung
gener
antimicrobi
respons
sinc
effect
vaccin
formul
requir
induct
persist
protect
memori
respons
cmi
elicit
nondispens
prerequisit
valid
vaccin
question
could
rather
cellular
antibodi
effector
immun
mostli
involv
antifung
protect
question
remain
relev
vaccin
sinc
approach
gener
vaccin
must
induc
persist
activ
cellular
effector
thu
sustain
elev
activ
proinflammatori
axi
may
quit
differ
one
reli
b
memori
cell
antibodi
immun
fact
becom
still
import
partial
total
immunodepress
subject
thu
natur
immun
antigen
immunodomin
epitop
interact
antigen
present
cell
mostli
dendrit
cell
process
mhc
class
ii
mhc
class
pathway
type
adjuv
determin
natur
elicit
immun
outcom
term
protect
support
cmi
effector
main
arm
protect
come
clinic
observ
welldefin
anim
model
show
instanc
abolit
cell
genet
knockout
cytokin
pattern
greatli
enhanc
suscept
experiment
infect
sever
fungi
dimorph
endem
pathogen
opportunist
one
addit
adopt
transfer
cell
immun
anim
shown
confer
protect
naiv
counterpart
mucos
system
model
infect
romani
santoni
et
al
calbican
recombin
ifngamma
protect
expectedli
knockout
ifngamma
anim
highli
suscept
infect
romani
human
situat
vari
natur
specif
infect
fungu
instanc
cmi
defect
innat
acquir
predispos
sever
form
mucocutan
system
candidiasi
aspergillosi
rather
recogn
neutropenia
main
predispos
condit
contrast
cryptococc
meningoenceph
pneumonia
pneumocysti
carinii
deepseat
infect
dimorph
fungi
hystoplasmosi
coccidiodomycosi
clearli
favour
cmi
defect
typic
aid
subject
clearli
fungicid
neutrophil
macrophag
may
better
job
activ
cytokin
interferongamma
type
interferon
tnfalfa
also
mention
case
direct
antifung
activ
cytotox
effector
cell
detect
exvivo
experi
though
vivo
relev
observ
remain
establish
forgotten
type
cytokin
respons
critic
request
format
highli
protect
antibodi
protein
polysaccharid
antigen
eg
differ
antibodi
other
thu
observ
cmi
delet
modif
enhanc
diseas
per
se
definit
proof
cellular
effector
protect
eventu
involv
moreov
variou
antibodi
gener
evid
protect
anim
model
cellular
cmi
effector
elicit
advoc
respons
protect
casadeval
et
al
suggest
cmi
induct
eventu
regul
accompani
gener
protect
antibodi
even
one
evid
case
critic
role
cmi
effector
control
infect
coccidioidomycosi
cox
mage
recent
report
candid
vaccin
antigen
describ
gener
potenti
protect
antibodi
tarcha
et
al
dna
vaccin
believ
strongest
immun
approach
cytotox
effector
gener
owe
preferenti
antigen
process
mhc
class
pathway
nonetheless
dna
vaccin
use
pneumocysti
gene
code
kexin
furinlik
proteas
ligand
adjuv
recent
shown
gener
antipcarinii
protect
antibodi
replet
mice
zheng
et
al
anoth
approach
vaccin
pneumocystosi
use
cell
wallassoci
glutam
acidrepeatrich
protein
amino
acid
smulian
et
al
demonstr
partial
protect
rat
pneumonia
accompani
cmi
antibodi
respons
final
antibodi
major
surfac
glycoprotein
gpa
fungu
manifestli
protect
independ
presenc
cell
harmsen
et
al
remark
pneumocystosi
clinic
major
exampl
diseas
caus
cell
defici
aid
three
consider
would
speak
cmi
effector
cell
uniqu
predominantli
exploit
vaccin
protect
maintain
persistentactiv
cmi
effector
usual
acquir
whole
cell
dna
vaccin
posit
control
infecti
agent
may
nonetheless
induc
strong
inflamm
potenti
untoward
effect
classic
koch
phenomenon
case
tuberculosi
may
easili
happen
endem
dimorph
fungi
like
coccidioid
show
reactiv
diseas
cox
mage
true
immun
system
evolv
potent
mean
regul
inflamm
hyperactiv
cmi
cellular
effector
regulatori
cell
counteract
cytokin
practic
bacteri
viral
vaccin
success
use
far
owe
protect
effect
antibodi
particularli
toxinneutr
antibodi
plotkin
orenstein
vaccin
conceiv
stimul
cmi
respons
cytotox
effector
accompani
array
citoand
chemokin
thu
mimick
consid
protect
immun
respons
case
hiv
new
antitb
vaccin
prove
extrem
difficult
achiev
despit
strong
effort
invest
recent
deep
et
al
contend
cell
antibodi
chief
mediat
protect
immun
blastomycosi
histoplasmosi
also
emphas
remark
difficulti
gener
type
vaccin
memorybound
antibodi
induc
vaccin
atrisk
subject
becom
immunosuppress
rel
longev
igg
iga
persist
good
protect
titer
serum
mucos
secret
even
rel
prolong
immunosuppress
period
like
sever
exampl
approach
may
work
one
last
protect
achiev
pneumocystosi
cortisonetr
rat
follow
vaccin
antigen
vaccin
kexin
ligand
dna
format
deplet
mice
smulian
et
al
zheng
et
al
clearli
achiev
vaccin
mere
elicit
antifung
cell
activ
macrophag
neutrophil
role
cmi
rule
antibodi
particip
antifung
protect
posit
evid
antibodi
inde
role
clinic
evid
antibodi
protect
fungal
infect
rather
limit
case
mathew
et
al
mathew
burni
recent
year
rather
strong
evid
accumul
protect
role
antibodi
experiment
model
close
human
diseas
directli
relat
use
variou
vaccin
formul
tabl
also
thank
pioneer
studi
arturo
casadeval
colleagu
albert
einstein
colleg
medicin
new
york
convinc
explan
difficulti
obtain
clinic
evid
antibodi
role
protect
cneoforman
recent
calbican
appear
attribut
exist
inhibitori
antibodi
rather
absenc
protect
one
casadeval
torr
et
al
bromuro
et
al
situat
like
present
fungal
infect
humancommens
environment
one
may
explain
variabl
inconsist
result
obtain
mani
fungal
whole
cell
vaccin
turn
exist
inhibitori
antibodi
make
new
hurdl
gener
subunit
vaccin
base
antibodymedi
protect
requir
critic
definit
discrimin
antigen
prepar
exclus
stimul
product
protect
antibodi
specif
also
isotyp
casadeval
meanwhil
demonstr
protect
antifung
antibodi
open
way
use
immunoprophylact
immunotherapeut
agent
fungi
ie
feasibl
passiv
vaccin
intervent
sever
prospect
advantag
thu
deserv
great
attent
area
fungal
infect
use
cell
line
prime
dendrit
cell
adopt
vaccin
remain
counterpart
side
cmiinduc
vaccin
bozza
et
al
feldmess
histor
therapi
infect
immun
sera
preced
use
vaccin
antibiot
inde
therapeut
prophylact
antisera
diphtheria
mening
pneumonia
cite
use
soon
even
preced
discoveri
caus
agent
infect
practic
passiv
immun
larg
abandon
sera
non
protect
highli
protect
inde
simpli
either
non
avail
suffici
quantiti
toxic
even
caus
induct
sometim
lethal
hypersensit
reaction
foreign
protein
serum
sick
entri
antibiot
scene
also
contribut
push
serum
therapi
corner
nonetheless
passiv
vaccin
remain
viabl
medic
approach
use
standard
hyperimmun
human
immunoglobulin
prepar
preand
postexposur
prophylaxi
diseas
viral
hepat
measl
varicella
tetanu
rabi
limit
specif
limit
suppli
cours
major
disadvantag
prepar
togeth
risk
transmit
recipi
unrecogn
undetect
infecti
agent
viru
prion
quit
clear
presentday
recombin
dna
technolog
go
substanti
replac
foreign
sera
human
immunoglobulin
prepar
highlyspecif
human
human
antibodi
varieti
differ
format
traggiai
et
al
alreadi
occur
field
tumor
chronic
autoimmun
diseas
take
place
also
field
infect
though
slower
rate
necessari
see
instanc
beninati
et
al
zhang
et
al
sever
exampl
recombin
antibodi
fungal
infect
one
regulatori
approv
track
mycograb
mathew
burni
other
readi
enter
path
interestingli
number
devoid
fc
compon
suggest
work
effici
even
absenc
phagocyt
effector
cell
complement
monoclon
antibodi
candida
inde
need
fc
compon
pattern
complement
activ
deposit
cell
surfac
protect
casadeval
et
al
mochon
cutler
far
consist
evid
therapeut
effect
passiv
vaccin
provid
endem
dimorph
infect
caus
histoplasma
coccidioid
blastomyc
agent
typic
diseas
cellular
effector
activ
cytokin
advoc
protect
howev
initi
find
protect
antibodi
emerg
deep
tarcha
et
al
fact
therapeut
antibodi
gener
human
format
requir
presenc
fc
compon
particularli
import
implic
passiv
vaccin
opportunist
fungi
theori
antibodi
work
without
cooper
immun
system
also
heavili
immunocomprom
patient
leukopen
one
ie
true
set
major
patient
deepseat
fungal
infect
quantiti
cost
inher
pure
antibodi
approach
like
antibodi
therapi
use
synerg
effect
antimycot
suggest
mathew
recogn
antibodi
may
relev
control
fungal
infect
thu
possibl
correl
protect
vaccin
reflect
need
desir
function
must
vaccinationinduc
antibodi
alreadi
mention
opson
complement
deposit
consid
utmost
import
effect
protect
activ
passiv
vaccin
model
howev
antibodi
requir
presenc
cellular
effector
fulli
exert
activ
fact
ultim
strong
limit
function
immunesuppress
patient
antibodi
gener
follow
vaccin
owe
activ
inhibit
form
toxic
enzym
activ
high
relev
also
antibodi
counteract
cognat
adhesin
well
recogn
virul
trait
sever
fungi
calderon
fonzi
calderon
possibl
inhibit
biofilm
format
affect
biofilm
critic
factor
fungal
growth
diseas
induct
mechan
could
relev
vaccin
expect
gener
protect
antifung
antibodi
recent
shown
candida
albican
dualtarget
antiadhesin
domain
antibodi
ie
smallest
mw
around
geneticallyengin
antibodi
fragment
contain
three
complementarydetermin
antigenbind
region
exert
high
level
protect
mucos
system
rodent
candidiasi
de
bernardi
et
al
indirect
demonstr
mechan
also
provid
cneoforman
select
protect
nonprotect
antibodi
decreas
biofilm
format
vitro
martinez
candida
aspergillu
antibodi
inhibit
fungal
growth
even
kill
grow
fungal
cell
describ
antibodi
gener
vaccin
either
monoclon
antibodi
neutral
widespectrum
antimicrobi
killer
toxin
gener
intern
imag
toxin
call
idiotyp
vaccin
see
polonelli
et
al
casson
et
al
immun
stress
mannoprotein
shown
moragu
et
al
recent
glycoconjug
vaccin
compos
betaglucan
molecul
laminarin
diphtheria
toxoid
alreadi
use
carrier
protein
bacteri
vaccin
shown
gener
fungu
growth
inhibitori
antibodi
torosantucci
et
al
last
approach
warrant
specif
descript
origin
immunolog
mechan
protect
ie
direct
antifung
effect
appar
reli
upon
host
immun
cooper
also
potenti
repres
multitarget
antifung
vaccin
singl
prepar
crossspeci
immun
studi
confirm
suppos
identif
killer
toxin
receptor
molecul
idiotyp
vaccin
quot
may
fall
within
kind
approach
casson
et
al
usual
vaccin
prepar
fight
given
diseas
made
whole
attenu
inactiv
caus
microbi
agent
one
immunodomin
antigen
compon
socal
subunit
vaccin
see
tabl
nowaday
popular
mix
combin
pediatr
vaccin
aim
immun
simultan
multipl
diseas
instanc
tetanu
diphtheria
polio
pertussi
hepat
b
mixtur
antigen
caus
agent
use
case
vaccin
compos
relat
antigen
crossreact
strain
belong
bacteri
viral
speci
instanc
case
antitubercul
bcg
smallpox
vaccin
knowledg
exampl
literatur
singl
defin
antigen
could
use
protect
differ
pathogen
belong
quit
distant
famili
order
awar
previou
use
antigen
phylum
organ
immun
diseas
caus
microrgan
anoth
phylum
somewhat
surpris
view
exist
conserv
highli
immunogen
protein
instanc
hsp
mani
differ
pathogen
compound
peptidoglycan
lipopolisaccharyd
wide
share
among
bacteria
way
immunolog
dogma
ask
vaccin
specif
may
acquir
use
highli
specif
antigen
sort
oppos
counterpart
natur
immun
nonspecif
wide
crossreact
recognit
rule
lipolysaccharid
variou
glycan
inde
major
stimul
natur
immun
socal
pathogenassoci
microbi
pattern
pamp
bind
famili
tolllik
receptor
tlr
receptor
instanc
fungal
glucan
brown
gordon
seri
past
recent
investig
aim
find
novel
approach
passiv
activ
vaccin
human
opportunist
fungi
realiz
dogmat
specif
concept
contrast
natur
adapt
immun
could
revers
use
compound
anoth
phylum
organ
immun
fungi
thu
propos
betaglucan
constitu
laminarin
alga
laminaria
digitata
candid
antigen
singl
vaccin
potenti
protect
variou
differ
fungal
infect
torosantucci
et
al
importantli
investig
also
reveal
algal
glucanbas
vaccin
elicit
antibodi
direct
inhibitori
activ
pathogen
thu
ad
critic
advantag
requisit
vaccin
immunocomprom
subject
converg
approach
wider
purpos
use
monoclon
antibodi
neutral
widespectrum
antimicrobi
killer
toxin
immun
antigen
rais
antiidiotyp
antibodi
mimick
activ
killer
toxin
fungi
polonelli
et
al
two
approach
might
share
common
compon
definit
proven
antiidiotyp
killer
toxinmimick
antibodi
rais
immun
killer
toxin
neutral
monoclon
antibodi
recogn
constitu
cognat
antigen
betaglucan
structur
complex
glucos
homopolym
found
cell
wall
fungi
alga
bacteria
stone
masuoka
basic
molecular
structur
rel
homogen
although
type
bond
molecular
mass
overal
molecular
configur
may
variabl
depend
differ
microbi
sourc
bohn
biolog
wellknown
immunomodulatori
antitumor
properti
casson
brown
masuoka
knowledg
never
consid
vaccin
antigen
rather
immunomodul
recent
pamp
opportunist
fungal
pathogen
candida
albican
glucan
major
structur
compon
account
approxim
cell
wall
dri
weight
base
differ
solubl
alkali
acid
candida
glucan
differenti
alkalisolubl
polym
rel
low
molecular
weight
branch
acidsolubl
molecul
predominantli
compos
link
residu
alkaliacid
insolubl
highli
branch
complex
contain
grossli
equival
amount
linkag
complex
chitin
provid
form
structur
integr
fungal
wall
chattaway
et
al
casson
gener
accept
fungu
glucan
preferenti
enrich
linkag
possibl
famili
distinct
molecul
wide
interconnect
differenti
locat
play
distinct
structur
role
cell
wall
architectur
recent
model
cell
wall
structur
suggest
link
glucan
molecul
form
threediment
matrix
surround
fungal
cell
insid
close
plasma
membran
skelet
framework
strengthen
chitin
chain
wherea
outer
edg
glucan
moieti
link
gpianchor
cell
wall
mannoprotein
skelet
framework
kli
scheme
cell
wall
organ
calbican
shown
figur
human
pathogen
fungi
contain
beta
glucan
express
predomin
two
isom
quit
variabl
depend
fungu
form
growth
addit
betaglucan
replac
alfaglucan
dimorph
fungi
glucan
per
se
poor
saccharid
antigen
probabl
dullest
constitut
homopolymer
sequenc
glucopyranosyl
residu
fig
low
exclus
igm
isotyp
antibodi
level
mice
achiev
even
aggress
immun
schedul
pure
solubl
particul
glucan
antigen
bromuro
et
al
howev
polysaccharid
glucan
may
becom
strongli
immunogen
conjug
protein
carrier
find
lowlevel
anti
glucan
antibodi
serum
normal
healthi
human
subject
probabl
consequ
natur
exposur
glucanprotein
figur
immunogold
label
cell
wall
glucan
canida
albican
use
detect
differ
affin
glucan
configur
note
glucan
miolecul
also
present
cell
wall
surfac
detail
see
text
ref
torosantucci
et
al
complex
found
cell
wall
mani
fungi
chaffin
et
al
previou
evid
indic
us
vaccin
compos
intact
candida
saccharomyc
cell
treat
expos
glucan
rather
mannan
cell
surfac
confer
substanti
degre
protect
antibodi
could
involv
protect
bromuro
et
al
said
consid
vaccin
base
glycoconjug
molecul
carrier
protein
could
allow
simultan
immun
protect
varieti
pathogen
fungi
test
strength
crossimmun
even
transphylet
vaccin
elect
use
algal
laminarin
rather
glucan
extract
candida
fungi
also
avoid
possibl
contamin
immunodomin
fungal
antigen
eg
mannoprotein
carrier
protein
geneticallydetoxifi
diphtheria
toxoid
alreadi
safe
use
current
vaccin
select
shortli
novel
glycoconjug
met
expect
term
immunogen
protect
mucos
system
candidiasi
rodent
well
system
aspergillosi
mice
protect
clearli
due
antibodi
bound
preferenti
grow
hyphal
cell
wall
calbican
aspergillu
fumigatu
moreov
monoclon
antibodi
rais
vaccin
mice
recogn
high
affin
glucan
configur
mimick
protect
effect
immun
sera
also
bound
hyphal
cell
torosantucci
et
al
figur
exemplifi
left
panel
grey
blue
dot
refer
mice
inject
adjuv
crm
protein
respect
right
panel
grey
color
repres
cfu
crmalon
inject
anim
panel
yellow
colour
repres
valu
associ
lamcrm
conjug
immunioz
detail
see
torosantucci
et
al
immunogen
protect
activ
induc
vaccin
particular
figur
show
contrast
common
belief
molecul
present
also
cell
surfac
candida
aspergillu
least
hyphal
cell
fungi
observ
part
match
recent
report
major
glucan
receptor
bind
cell
surfac
calbican
gartner
et
al
glucan
constitu
therefor
present
fungal
cell
surfac
particularli
grow
hypha
thu
access
antibodi
opson
cell
facilit
complement
deposit
process
whose
import
protect
quit
obviou
highlight
sever
studi
casadeval
et
al
antibodi
cell
surfac
compon
calbican
shown
favour
intracellular
extracellular
kill
fungu
quit
recent
antibodi
shown
increas
candidacid
activ
macrophag
vitro
antibodi
bind
hyphal
form
growth
could
also
perturb
adher
tissu
invas
demonstr
recent
mab
direct
stressmannoprotein
calbican
moragu
et
al
may
contributori
factor
believ
properti
antibodi
may
truli
relev
fungal
crossspeci
protect
confer
vaccin
addit
mechan
alreadi
discuss
data
suggest
addit
mechan
protect
antibodi
could
oper
vivo
torosantucci
et
al
fact
immun
serum
vaccin
mice
exert
mark
inhibit
candida
aspergillu
hyphal
growth
vitro
effect
also
exert
affinitypurifi
iggrich
fraction
keep
preferenti
antibodi
bind
hypha
togeth
previou
data
obtain
yeast
killer
toxinmimick
antiidiotyp
antibodi
find
suggest
certain
antibodi
may
endow
direct
inhibitori
activ
fungi
sort
interact
viabilitycrit
molecul
possibl
includ
oligosaccharid
nascent
chain
bound
transglycosidas
glucan
synthasesin
accord
hypothesi
recent
data
laboratori
shown
immun
serum
lamcrmvaccin
mice
abl
inhibit
certain
stage
cell
wall
regener
protoplast
calbican
coincid
betaglucan
deposit
unpublish
data
observ
antibodi
inhibit
hyphal
growth
possibl
inhibit
one
critic
compon
cell
wall
machineri
particular
interest
sinc
least
candida
albican
probabl
also
aspergillu
steven
hypha
appear
carri
main
virul
trait
adhesin
proteas
contribut
fungu
pathogen
context
antibodi
would
work
sort
cell
wall
inhibitori
antibiot
addit
hypha
repeatedli
shown
confer
immunoevas
properti
fungu
probabl
activ
signal
pattern
contrast
product
protect
cytokin
axi
see
report
activ
pattern
bind
receptor
interestingli
term
immunoevas
hypha
bind
receptor
gartner
et
al
thu
theori
anti
glucan
antibodi
may
also
exert
protect
neutral
signal
mechan
shift
cytokin
profil
toward
protect
pattern
observ
alreadi
made
antibodi
experiment
cryptococcosi
casadeval
et
al
overal
antibodi
could
particularli
protect
express
altogeth
typic
properti
immunomodulatori
prodef
compon
associ
peculiar
inhibitori
properti
featur
sort
antibiot
action
whatev
mechan
novel
approach
crossimmun
vaccin
may
open
way
vaccin
least
major
opportunist
fungal
agent
highli
preval
incid
diseas
mostli
whether
could
shown
futur
studi
antibodi
rais
vaccin
still
present
suffici
titer
immunosuppress
therapi
caus
unbal
microbi
flora
untoward
effect
owe
wide
specif
approach
also
provid
novel
vaccin
could
use
rais
human
human
antibodi
passiv
immun
approach
ongo
laboratori
outcom
necessarili
requir
epitop
dissect
precis
identif
cognat
antigen
within
glucan
molecul
previous
neglect
vaccin
antifung
one
gain
step
public
health
prioriti
scale
increas
awar
medic
threat
repres
fungal
infect
advanc
knowledg
fungi
caus
diseas
immun
respons
may
keep
bay
togeth
improv
biotechnolog
approach
candid
vaccin
antigen
engin
antibodi
offer
critic
new
tool
antifung
vaccin
gener
fungal
vaccin
may
also
benefit
clearli
increas
advocaci
public
privat
sector
theori
practic
vaccin
unrival
riskand
costbenefit
ratio
brought
field
increas
enthusiasm
commit
discoveri
antibodi
may
play
critic
role
protect
also
give
strong
impetu
field
passiv
vaccin
may
eventu
prove
first
vaccin
applic
fungal
infect
also
help
spectacular
advanc
gener
human
human
monoclon
antibodi
variou
technolog
fragment
research
activ
passiv
vaccin
fungi
also
offer
novel
idea
innov
approach
field
vaccin
research
casadeval
pirofski
clearli
hope
year
ago
chanc
gener
get
approv
regulatori
author
one
antifung
vaccin
activ
passiv
use
human
next
year
